Prof. Aldo Tagliabue is a distinguished immunologist and vaccinologist with over 40 years of experience in immunology research and the development of vaccines and immunotherapeutic products. He held a senior scientific position at the Italian National Research Council and was a co-founder of Achilles Vaccines, an Italian biotechnology company. His career includes key roles at the Sclavo Research Center, Dompé, and Novartis, where he led multiple vaccine development initiatives.

In 1998, he founded ATLA SRL. in Milan, Italy, a scientific consulting firm that later evolved into ALTABIO. Over two decades, the company secured approximately 500 million € in research funding and collaborated extensively on vaccine R&D projects.

From 2002 to 2005, Prof. Tagliabue served as Director of Research and Development at the International Vaccine Institute (IVI) in Seoul, South Korea, established under the framework of the United Nations Development Programme (UNDP). At IVI, he was responsible for guiding research strategies and overseeing the implementation of vaccine development programs aimed at delivering safe, effective, and affordable vaccines for global public health.

In 2006, Professor Tagliabue returned to Italy at the invitation of Novartis to help establish the Novartis Vaccine Institute for Global Health, where he guided the development of new vaccines targeting diseases in developing countries.